Fig 1: The expression of TLR2, BST2, and LGALS3 protein in AHLSC of SOD1G93A mouse. Immunofluorescence staining and intensity analysis of TLR2 (A), LGALS3 (B), and BST2 (C) in the AHLSC of 40- and 90-day ALS mice. The right panel shows the quantitative results, *p < 0.05, ** p < 0.01, Scale Bar = 50 μm. The values are expressed as mean ± SD, *p < 0.05 versus age-matched WT mice, **p < 0.01 versus age-matched WT mice, n = 4 in each group.
Fig 2: CD157 interacts with TLR2 and PKCzeta to enhance macrophage ROS production. Peritoneal macrophages from WT mice and Cd157 KO mice infected with strain H37Ra (MOI of 5) for 3 h in the presence or absence of sCD157 (5 μg/ml) or anti-TLR2 (20 μg/ml). cROS production was determined by FACS. (A and B) The representative cROS production (A) and the averaged cROS MFI (B) were detected. (C) Peritoneal macrophages from Cd157 KO mice were infected with strain H37Ra (MOI of 5) in the presence or absence of sCD157 (5 μg/ml) or anti-TLR2 (20 μg/ml). At 72 h postinfection, the number of CFU was determined. (D) Peritoneal macrophages from WT mice infected with strain H37Ra were analyzed for TLR2 (green) and CD157 (red) expression on macrophages by immunofluorescence staining. The bar represents 20 μm in small pictures at a magnification of ×80. The gray arrows indicate a region of colocalization. (E) Peritoneal macrophages from WT and KO mice infected with strain H37Ra (+) (MOI of 5) for 12 h or not infected with strain H37Ra (−) were lysed and immunoprecipitated (IP) with anti-TLR2 antibody. Immunoprecipitates were then immunoblotted (IB) for TLR2 and PKCzeta. (F) Peritoneal macrophages from Cd157 KO mice were infected with M. tuberculosis H37Ra (MOI of 5) in the presence or absence of PKCzeta inhibitor (20 μM) or sCD157 (5 μg/ml). CFU was assessed 72 h postinfection. Peritoneal macrophages from WT mice and Cd157 KO mice infected with strain H37Ra (MOI of 5) for 3 h in the presence or absence of sCD157 (5 μg/ml) or PKCzeta inhibitor (20 μM). cROS production was determined by FACS. (G and H) The representative cROS production (G) and the averaged cROS MFI (H) were detected. One-way ANOVA Newman-Keuls multiple comparison test (B, C, F, and H) was used. Values are means plus SEM of duplicate determinations of two independent experiments. *, P ≤ 0.05, ***, P ≤ 0.001.
Fig 3: The immunofluorescent staining of BST2, TLR2, and LGALS3 on microglia or astrocytes. (A,B) Double immunofluorescent staining of BST2 in the AHLSC of 90-day ALS mice. The Iba1-labeled microglia (A) and GFAP-labeled astrocyte (B) in 90-day ALS mice. (C,D) The results for TLR2. (E,F) The results for LGALS3; Scale bar = 50 μm.
Fig 4: The effects of morphology remodeling of Aβ42 species by P2CSKn on phagocytosis.a The cellular distribution of TLR2 and sFITC-Aβ42 (0.5 μM) with or without pretreatment with RhoB-P2CSKn (1.0 μM). Images were recorded using LSCM and colocalization analysis was performed using Image J (v 1.54g). b CETSA of TLR2 in BV2 cells in the presence of 2.0 eq. P2CSKn pretreated sAβ42 examined by Western blot. c Cell viability of BV2 cells in the presence of various concentrations of P2CSKn for 24 h, as determined using CCK8 assay. d Effects of different compounds (1.0 μM) and Aβ42 (0.5 μM) on the apoptosis in BV2 cells. Green dots indicate fluorescence released by activated capases-3 from GreenNucr Caspase-3 Substrate. e Expression of cleaved forms of PARP and caspase-3 in BV2 cells treated with sAβ42 or fAβ42, and P2CSKn, and P2CSKn pretreated sAβ42, respectively, as measured using Western Blot after 12 h incubation. f Expression of cleaved forms of PARP in BV2 cells treated with different Aβ42 species as measured using Western Blot after 12 h incubation. Treatment & Wash group refers to P2CSKn preincubated with cells and washed off before sAβ42 (0.5 μM) addition. g Phagocytosis of 0.5 μM sFITC-Aβ42 with or without compounds (1.0 μM) in BV2 cells, as determined using Flow cytometry. Normal group refers to sFITC-Aβ42 pretreated with P2CSKn or Pam2CSK4 for 30 min before addition to cells; Treatment & Wash group refers to P2CSKn or Pam2CSK4 preincubated with cells and washed off before sFITC-Aβ42 (0.5 μM) addition. Cells were incubated with different FITC-Aβ42 samples for 12 h. Data are representative of three independent experiments with similar results in (a, d), three independent experiments in (b, f, g), two independent experiments in (e). Data are presented as mean ± SD, n = 3 (b, f, g), n = 6 (c) independent samples using one-way ANOVA with Dunnett’s post hoc test (c, d, f) or two-tailed t tests (g). ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Exact p values were given in the Source Data file. Source data are provided as a Source Data file.
Fig 5: The effects of BV2 cell activation on P2CSKn-facilitated phagocytosis.a The phagocytosis of 0.5 μM sFITC-Aβ42 and fFITC-Aβ42, as well as preformed hPFAβ42 (0.5 μM sFITC-Aβ42 pretreated with 1.0 μM P2CSKn) in TLR2-WT and TLR2-knockdown BV2 cells, as determined by Flow cytometry. NC: negative control. b Effects of P2CSKn (0.5 μM) and different forms of Aβ42 (0.5 μM) on the mRNA expression of iNOS and Tnfα in BV2 cells, as determined using rt-qPCR. hPAβ42 was performed by treating 0.5 μM sAβ42 with 1.0 μM P2CSKn. c Protein levels of MARCO, MSR1, TLR2 and NLRP3 in BV2 cells treated with fAβ42 (0.5 μM), 1.0 μM P2CSKn, Pam2CSK4 or KLVFFn, and 1.0 μM P2CSKn, Pam2CSK4 or KLVFFn-pretreated sAβ42 (0.5 μM), respectively. Cell lysate was harvested after 12 hr incubation and examined using Western Blot. d mRNA expression of Marco and Msr1 in BV2 cells treated with fAβ42 (0.5 μM), 1.0 μM P2CSKn, Pam2CSK4 or KLVFFn, as well as 1.0 μM P2CSKn, Pam2CSK4 or KLVFFn-pretreated sAβ42 (0.5 μM), for 12 hr, respectively. mRNA level of each gene was determined by rt-qPCR. e Immunofluorescence of Iba1 in TLR2-WT or TLR2-knockdown BV2 cells treated with P2CSKn (1.0 μM), 0.5 μM sAβ42, fAβ42, and preformed hPAβ42 by treating 0.5 μM sAβ42 with 1.0 μM P2CSKn. f Phagocytosis of fFITC-Aβ42 in BV2 cells with or without pretreatment of 1.0 μM P2CSKn or Pam2CSK4, respectively, as determined using Flow cytometry. P2CSKn or Pam2CSK4 was added to the cells for 6 h then washed before addition of fFITC-Aβ42 for 12 h incubation with cells. Data are representative of three independent experiments with similar results in (e), or three independent experiments in (a–d, f). Data are presented as mean ± SD, n = 3 independent samples in (a-d,f) using one-way ANOVA with Dunnett’s post hoc test (b–f) or two-tailed t tests (a). ns, not significant, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Exact p values were given in the Source Data file. Source data are provided as a Source Data file.
Supplier Page from Abcam for Anti-TLR2 antibody [6C2]